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Rifaximin is a rifampicin derivative, poorly absorbed by the gastro-intestinal tract. We studied the
in vitro susceptibility to rifamixin of 1082 Clostridium difficile isolates; among these,184 isolates
from a strain collection were tested by an in-house rifaximin disc (40 mg) diffusion test, by an in-
house rifaximin broth microdilution test, by rifampicin Etest and by rpoB gene sequencing. In the
absence of respective CLSI or EUCAST MIC breakpoints for rifaximin and rifampicin against C.
difficile we chose MIC ¢32 mgm l
”1 as criterion for reduced in vitro susceptibility. To further
validate the disc diffusion test 898 consecutive clinical isolates were analysed using the disc
diffusion test, the Etest and rpoB gene sequence analysis for all resistant strains. Rifaximin broth
microdilution tests of the 184 reference strains yielded rifaximin MICs ranging from 0.001 (n51)
to ¢1024 mgm l
”1 (n561); 62 isolates showed a reduced susceptibility (MIC ¢32 mgm l
”1). All
of these 62 strains showed rpoB gene mutations producing amino acid substitutions; the
rifampicin- and rifaximin-susceptible strains showed either a wild-type sequence or silent amino
acid substitutions (19 strains). For 11 arbitrarily chosen isolates with rifaximin MICs of .1024
mgm l
”1, rifaximin end-point MICs were determined by broth dilution: 4096 mgm l
”1 (n52),
8192 mgm l
”1 (n56), 16 384 mgm l
”1 (n52) and 32 678 mgm l
”1 (n51). Rifampicin Etests on
the 184 C. difficile reference strains yielded MICs ranging from ¡0.002 (n5117) to ¢32 mg
ml
”1 (n559). Using a 38 mm inhibition zone as breakpoint for reduced susceptibility the use of
rifaximin disc diffusion yielded 59 results correlating with those obtained by use of rifaximin broth
microdilution in 98.4% of the 184 strains tested. Rifampicin Etests performed on the 898 clinical
isolates revealed that 67 isolates had MICs of ¢32 mgm l
”1. There were no discordant results
observed among these isolates with reduced susceptibility using an MIC of ¢32 mgm l
”1 as
breakpoint for reduced rifampicin susceptibility and a ,38 mm inhibition zone as breakpoint for
reduced rifaximin susceptibility. The prevalence of reduced susceptibility was 7.5% for all isolates
tested. However, for PCR ribotype 027 the prevalence of reduced susceptibility was 26%.
Susceptibility testing in the microbiology laboratory therefore could have an impact on the care
and outcome of patients with infection. Our results show that rifaximin – despite its water-
insolubility – may be a suitable candidate for disc diffusion testing.
INTRODUCTION
Clostridium difficile is a spore-forming Gram-positive
anaerobic bacterium and a major cause of nosocomial
and community-acquired diarrhoea (Wistro ¨m et al., 2001).
Metronidazole and oral vancomycin are the main anti-
biotics used to treat C. difficile infection (CDI). In 2005, in
Austria, oral rifaximin was licensed for ‘treatment of
gastrointestinal diseases caused or partially caused by
rifaximin-susceptible bacteria, e.g. gastrointestinal infections,
pseudomembranous colitis due to C. difficile, hepatic
encephalopathy, small bowel bacterial overgrowth and
diverticulitis’ (Willerroider, 2009). However, to our know-
ledge, no guidelines have yet been published to test in vitro
susceptibility of C. difficile to rifaximin. Two study groups
previously used ¢32 mg l
21 (O’Connor et al., 2008; Jiang
et al., 2010) as breakpoint for resistance using agar dilution
testing, a method not widely employed in routine testing of Abbreviation: CDI, Clostridium difficile infection.
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concentrations (4000 to 8000 mgg
21) in stools 3 days after
a single oral administration. Johnson et al. (2007) reported
on the possible prevention of recurrence of CDI by
administering rifaximin immediately after completion of
the last course of vancomycin therapy of CDI.
In Austria, rifaximin is widely used to treat CDI, and
microbiological laboratories often receive requests for in
vitro susceptibility testing of clinical C. difficile isolates
against this substance. The aim of this study was to
evaluate whether the disc diffusion method can be applied
to test in vitro susceptibility of C. difficile to rifaximin.
METHODS
Micro-organisms. One hundred and eighty-four C. difficile isolates
were obtained from the reference strain collection of the Austrian
national C. difficile reference centre, including ATCC strain 9689, and
50 strains previously provided by Leeds University Hospital (UK), 3
strains from the Public Health Laboratory Maribor (Slovenia) and 24
strains from Leiden University Hospital (Netherlands). In addition,
898 non-duplicate clinical isolates were tested, cultured in 21 Austrian
medical laboratories in 2009.
All 1082 isolates were stored at 280 uC in cryobank tubes (Mast
Diagnostics) until testing. Isolates were recultivated on Columbia
blood agar plates (bioMe ´rieux); all were tested for PCR ribotype (RT)
(Indra et al., 2008), toxin A (A) (van den Berg et al., 2004), toxin B
(B) (Kato et al., 1991, 1999), binary toxin (BT) (Stubbs et al., 2000)
and tcdC deletion (Spigaglia & Mastrantonio, 2002). Tables 1 and 2
list the PCR ribotypes of these isolates. All 1082 isolates except one
(PCR ribotype 010) produced at least toxin B; 149 of them (14%)
were A/B/BT positive and belonged to the following ribotypes: 027
(n599), 078 (n510), 176 (n59), 023 (n55), 080 (n53), 126 (n52),
419 (n52), 045 (n52), 411 (n52), 429 (n52), 250 (n51), 413
(n51), 018 (n51), 515 (n51), 344 (n51), 605 (n51), 606 (n51),
616 (n51), 654 (n51), 655 (n51), 656 (n51), 657 (n51), 658
(n51). If possible nomenclature was used according to that given by
the John Brazier’s laboratory, due to the higher quality of resolution
gained with capillary sequencer-based PCR-ribotyping (Indra et al.,
2008) strains not assigned by John Brazier’s laboratory were given
numbers starting with 400.
Antimicrobial agents and susceptibility testing. The 184 isolates
from the strain collection were tested by an in-house rifaximin disc
(40 mg) diffusion test (Oxoid; custom-made product), by an in-house
rifaximin broth microdilution test and by rifampicin Epsilon-test
(Etest) (bioMe ´rieux). The 898 clinical isolates from 2009 were tested
only by disc diffusion test and rifampicin Etest (bioMe ´rieux).
Rifaximin discs were custom-made (Oxoid) by Gebro Pharma. The
disc diffusion tests were performed on Brucella blood agar plates
supplemented with 5 mg haemin l
21 and 1 mg vitamin K l
21
(Oxoid).
The rifaximin broth microdilution test was performed as follows.
Rifaximin was purchased as a powder from Alfa Wassermann. Sterile
stock solutions were prepared according to the instructions of CLSI
for testing of anaerobes (Clinical and Laboratory Standards Institute,
2007). In short, rifaximin was dissolved in methanol and then diluted
in 0.9% saline solution. Serial twofold dilutions in ATB S-medium
containing menadione (vitamin K3) at 0.5 mg l
21 and haemin at
15 mg l
21 (bioMe ´rieux) were prepared for rifaximin concentrations
covering a range from 0.000125 to 1024 mgm l
21; 96-well microdilu-
tion plates were filled with ATB S-medium (bioMe ´rieux) containing
the respective antibiotic concentrations. The antibiotic stocks were
freshly prepared on the day of testing. For inoculum preparation, test
organisms were cultured for 48 h anaerobically on Columbia blood
agar plates (bioMe ´rieux) at 37 uC; bacteria were suspended in 0.9%
saline solution to yield McFarland 0.5 and diluted 1:10 into the
medium, so that the final test concentration of bacteria was
approximately 1610
6 c.f.u. ml
21. Minimal inhibitory concentration
(MIC) was defined as the lowest concentration at which no growth
was observed after incubation for 48 h at 37 uC in an anaerobic
atmosphere using anaerobic jars and GasPak (BD). Growth controls
were performed by inoculation of antibiotic-free medium with an
aliquot of the primary inoculum at a concentration of 10
5 c.f.u. per
well; purity testing was performed by transferring an aliquot of 10 ml
onto two Columbia blood agar plates with incubation under aerobic
and anaerobic conditions, respectively.
Rifampicin Etests (MIC range 0.002–32 mgm l
21) were performed
according to the manufacturer’s instructions (bioMe ´rieux) using
Brucella blood agar plates supplemented with haemin (5 mg l
21) and
vitamin K (1 mg l
21) (Oxoid).
In the absence of respective CLSI or EUCAST MIC breakpoints for
rifaximin and rifampicin against C. difficile we chose MIC ¢32 mg
ml
21 as criterion for reduced in vitro susceptibility, as suggested by
O’Connor et al. (2008) and Jiang et al. (2010). Setting of zone
Table 1. Distribution of ribotypes among 184 C. difficile
isolates from the strain collection of the Austrian national C.
difficile reference centre
Ribotype No. of strains Percentage
027 26 14.13
053 16 8.70
001 7 3.80
014/0 6 3.26
005 3 1.63
056 3 1.63
078 3 1.63
239 3 1.63
408 3 1.63
002/2 2 1.09
012 2 1.09
017 2 1.09
020 2 1.09
029 2 1.09
031 2 1.09
043 2 1.09
046 2 1.09
404 2 1.09
503 2 1.09
510 2 1.09
Other* 92 50
*Represented by one isolate each: 002/0, 002/1, 003, 004, 006, 007,
009, 010, 014, 015, 016, 018, 019, 023, 025, 026, 033, 035, 036, 037,
039, 040, 042, 045, 047, 049, 050, 051, 052, 054, 055, 057, 058, 060,
062, 063, 064, 066, 067, 068, 070, 072, 075, 076, 077, 079, 080, 081,
083, 084, 085, 087, 094, 095, 106, 115, 117, 118, 122, 126, 131, 153,
169, 174, 201, 209, 212, 220, 411, 413, 434, 441, 444, 448, 466, 497,
504, 523, 524, 539, 542, 548, 622, 627, 633, 643, 649, 650, 651, 652,
653, 654.
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(40 mg) diffusion was performed according to the recommendations
of Turnidge & Paterson (2007).
Statistical analyses were performed with STATA/IC 10.1 (StataCorp).
Detection of single-nucleotide polymorphisms (SNPs) within
the rpoB gene. DNA was extracted from cultures using the MagNA
Pure Compact (Roche Diagnostics) according to the producer’s
manual to a final volume of 50 ml. Primers RifFOR (59-CAAGATA-
TGGAAGCTATAAC-39) and RifREVlang (59-GTGATTCTATAAAT-
CCAAATTC-39) were used in PCRs containing 25 ml HotStar Taq
Master Mix (Qiagen), 5 ml( 5p m o lml
21) of each primer, 13 ml
water and 2 ml DNA. Amplification was performed in a PCR
thermocycler (15 min 96 uC, 30 cycles of 1 min 94 uC, 1 min 52 uC
and 1 min 72 uC, and finally 10 min 72 uC). PCR products
were cleaned up with Escherichia coli exonuclease I, and shrimp
alkaline phosphatase (Fermentas) according to the manufacturer’s
instructions.
Sequencing PCR containing 2 ml Big-Dye-Mix (Applied Biosystems),
1 ml Sequencing Buffer (Applied Biosystems) 4 ml water, 1 ml RifFOR
or RifREVlang primer (10 pmol
21) and 2 ml DNA was performed in a
commercial PCR thermocycler (1 min 96 uC, 30 cycles of 20 s 96 uC,
20 s 50 uC and 4 min 60 uC). The amplified products were cleaned
up with Centri Sep 96-well plates or Centri Sep 8 well strips (Applied
Biosystems) for dye terminator clean-up according to the manufac-
turer’s manual. Samples were analysed in an ABI 3130 genetic
analyser (Applied Biosystems) with 36 cm capillary loaded with a
POP7 gel (Applied Biosystems).
Sequences were analysed for the presence of SNPs within the rpoB
gene using Kodon (Applied Maths) version 3.5 by aligning the
samples to the rpoB gene sequence of a reference wild-type C.
difficile strain (CD630; NC_009089) downloaded from the NCBI
database.
RESULTS
Results for reference strains
Rifaximin disc (40 mg) diffusion testing of the 184 reference
strains yielded inhibition zone diameters ranging from
6 mm to 74 mm. Rifaximin broth microdilution tests of the
184 reference strains yielded rifaximin MICs ranging from
0.001 (n51) to ¢1024 mgm l
21 (n561); 62 strains showed
reduced susceptibility with an MIC of at least 32 mgm l
21.
The MIC50 of rifaximin was 0.032 mgm l
21 and the MIC90
was ¢1024 mgm l
21; the inhibition diameters in compar-
ison to the results obtained by broth microdilution test are
summarized in Fig. 1. The most common rpoB mutation
found within this group was R505K (n546); other
mutations were H502N+R505K (n56), H502Y (n52),
H502N (n52) and one each of H502L, H502N+A555A,
L487F+H502Y, R505K+I548M, D492V and S550F.
For 11 arbitrarily chosen strains with rifaximin MICs of
.1024 mgm l
21, rifaximin end-point MICs were deter-
mined by broth dilution: 4096 mgm l
21 (n52: strains 2228
and 2639), 8192 mgm l
21 (n56: strains 2236, 2285, 2312,
2383, 2816 and 3025), 16384 mgm l
21 (n52: strains 3091
and 910016) and 32678 mgm l
21 (n51: strain 3098). These
11 strains yielded the following mutations in their rpoB
genes: R505K (strains 2228, 2236, 2285, 2312, 2383, 2639,
3091 and 910016), L487F+H502Y (strain 2816), H502N+
R505K (strain 3025), R505K+I548M (strain 3098).
Rifampicin Etests on these 184 C. difficile strains yielded
MICs ranging from ¡0.002 (n5117) to ¢32 mgm l
21
(n559); 59 strains had reduced susceptibility (MIC
¢32 mgm l
21). The MIC50 of rifampicin was ¡0.002 mg
ml
21 and the MIC90 was ¢32 mgm l
21; all 59 strains
showed mutations in the rpoB region (R505K (n546),
H502N+R505K (n56), H502Y (n52) and one each
of H502L, S550F, H502N+A555A, L487F+H502Y,
Table 2. Distribution of ribotypes among 898 clinical C.
difficile isolates from 2009
Ribotype No. of strains Percentage
053 198 22
014/0 81 9.0
027 73 8.1
002/2 35 4.0
001 28 3.1
005 26 2.8
‘Infrequent’ ribotypes
(n510–25)*
161 17.8
‘Rare’ ribotypes (n5,10)D 296 33.2
*010, 012, 018, 020, 029, 078, 241, 408, 600.
D003, 009, 014/5, 015, 017, 019, 023, 025, 026, 031, 043, 045, 046, 049,
054, 056, 066, 070, 080, 081, 087, 126, 153, 176, 203, 205, 206, 207,
208, 209, 211, 212, 220, 232, 236, 237, 239, 250, 403, 404, 405, 411,
413, 415, 419, 425, 429, 430, 431, 432, 434, 438, 439, 440, 441, 442,
448, 449, 451, 453, 457, 470, 472, 477, 481, 483, 484, 486, 492, 495,
496, 498, 499, 500, 501, 502, 503, 504, 505, 507, 508, 510, 512, 514,
515, 516, 518, 519, 520, 523, 525, 526, 530, 531, 532, 535, 537, 542,
548, 549, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612,
613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626,
627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640,
641, 642, 643, 644, 645, 646, 647, 648, 655, 656, 657, 658.
Fig. 1. Rifaximin disc (40 mg) diffusion testresults of 184 C. difficile
reference strains compared to MICs obtained by the rifaximin broth
microdilution test. All measured ‘sensitive’ C. difficile strains
(n5122) are grouped in quadrant A, in contrast to the 62 strains
identified as ‘reduced susceptibility’ in quadrant B.
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1208 Journal of Medical Microbiology 60R505K+I548M). In 181 (98.4%) of the 184 strains tested, the
use of the rifampicin Etest yielded results (reduced suscep-
tibilityornon-resistant)inaccordancewiththoseobtainedby
the rifaximin broth microdilution test. Discordant results
(rifaximin vs rifampicin) were found for three strains. Strain
2347/655 (showing an H502N rpoB mutation) and 3153/PCR
ribotype 002/0 (showing a D492V rpoB mutation) had a
rifaximin broth microdilution MIC of ¢1024 mgm l
21 and a
rifampicin Etest MIC of 0.064 mgm l
21 and 1 mgm l
21,
respectively. Strain Lee047/PCR ribotype 047 had a rifaximin
broth microdilution MIC of 64 mgm l
21 and a rifampicin
Etest MIC of 0.25 mgml
21. Molecularanalyses of these strains
revealed a mutation in the rpoB gene giving an H502N amino
acid substitution (Table 3).
Using an inhibition zone of ,38 mm as breakpoint for
reduced susceptibility, the use of rifaximin disc diffusion
yielded results correlating with those received by the use of
rifaximin broth microdilution in 180 (97.8%) of the 184
strains tested. Strain 2203/PCR ribotype 053 and 3018/PCR
ribotype 018 had rifaximin inhibition zones of 32 mm and
rifaximin broth microdilution MICs of 1 mgm l
21 and
showed an H502N or S550Y rpoB gene mutation,
respectively. Strain 3109/PCR ribotype 002/0 had a
rifaximin inhibition zone of 30 mm and a rifaximin broth
microdilution MIC of 16 mgm l
21 and showed a number of
silent mutations (T501T, L506L, G510G, G512G, F521F,
E541E, K556K) in the rpoB gene. Strain 3141/PCR ribotype
539 had a rifaximin inhibition zone of 16 mm and a
rifaximin broth microdilution MIC of 4 mgm l
21, and also
showed a number of silent mutations (S475S, F481F,
D492D, T501T, A508A, G510G, T539T, K556K) (Table 3).
The 58 strains with reduced susceptibility to rifampicin and
rifaximin showed rpoB gene amino acid substitutions as
follows: R505K (n546), H502N+R505K (n55), H502Y
(n52) and one each of H502L, S550F, H502N+A555A,
L487F+H502Y and R505K+I548M.
Of the 117 rifampicin- and rifaximin-susceptible strains
with MICs of ¡0.002 mgm l
21, 98 (84%) showed no point
mutations in rpoB; 19 showed only silent amino acid sub-
stitutions as follows: T501T+L506L+G510G+G512G+
F521F+E541E+K556K (n511), A555A (n56), L500L (n52).
Correlation of rifampicin MICs obtained by broth dilution
with rifaximin disc diameters was tested by Kendall’s tau-b
correlation coefficient: 20.42 (P,0.001 for the hypothesis
that both parameters were independent).
Results for clinical isolates
Rifaximin disc (40 mg) diffusion testing performed on 898
clinical C. difficile isolates yielded inhibition zone dia-
meters ranging from 6 mm (n567) to 78 mm (n52) (Fig.
2). Using an inhibition zone ,38 mm as breakpoint for
reduced susceptibility a total of 68 strains with reduced
susceptibility were identified.
Rifampicin Etests performed on the 898 isolates revealed
that 67 isolates had MICs of ¢32 mgm l
21 for rifampicin
and that 819 had MICs of ¡0.002 mgm l
21; 12 isolates
(1.3%) exhibited rifampicin MICs between these extremes.
By rifaximin disc diffusion test, the 67 strains with reduced
rifampicin susceptibility exhibited no inhibition zone. No
discordant results were observed among these 67 isolates
with reduced susceptibility using an MIC of ¢32 mgm l
21
as breakpoint for reduced rifampicin susceptibility and a
,38 mm inhibition zone as breakpoint for reduced rifaxi-
min susceptibility. Isolate 2663/PCR ribotype 053 had a
rifampicin Etest MIC of 0.064 mgm l
21 and a rifaximin
inhibition zone of 36 mm; molecular analyses revealed a
D492N mutation in the rpoB gene (Table 3).
Table 3. Amino acid substitutions detected by rpoB sequence analysis in C. difficile strains with
discordant results
Isolate
ID no.
rpoB mutation* Rifampicin MIC
(mgm l
”1)
Rifaximin MIC
(mgm l
”1)
Rifaximin DDD
inhibition zone (mm)
2203 H502N 0.5 1 32
2347 H502N 0.064 ¢1024 34
2663 D492N 0.064 1 36
3018 S550Y 0.016 1 32
3109 T501T, L506L, G510G,
G512G, F521F, E541E,
K556K
0.125 16 30
3141 S475S, F481F, D492D,
T501T, A508A, G510G,
T539T, K556K
44 1 6
3153 D492V 1 ¢1024 26
Lee047 H502N 0.25 64 30
*Resulting amino acid substitution shown.
DDD, disc diffusion.
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All the rifamycins are semisynthetic derivatives of rifamycin
B, a fermentation product of Amycolatopsis mediterranei,
formerly named Streptomyces mediterranei. Rifamycin B
exerts poor antimicrobial activity, but is easily produced and
readily converted chemically into rifamycin S, from which
most active derivatives are prepared (Parenti & Lancini,
2003). Rifaximin is a semi-synthetic derivative of rifamycin
S formulated for oral administration. In the 1980s it was
only available in Italy, but today it is marketed worldwide
mainly for the treatment of gastrointestinal infections and
the treatment of chronic hepatic encephalopathy (Corazza
et al., 1988; Festi et al., 1992). Jiang et al. (2000) reported
high rifaximin concentrations (4000 to 8000 mgg
21)i n
stools 3 days after single oral administration.
Although adequate antimicrobial drug concentrations
should be achieved by the high dosage of the non-
absorbable rifaximin, the constraints imposed by possible
drug resistance (O’Connor et al., 2008) often impel
clinicians to request in vitro susceptibility testing of C.
difficile isolates from patients not responding to therapy.
Our results on 11 arbitrarily chosen isolates from the group
with reduced susceptibility to rifaximin (MIC .1024 mg
ml
21) showed MICs ranging from 4096 to 32 678 mgm l
21,
so that a breakpoint for resistance between .32 mgm l
21
and 1024 mgm l
21 can be considered for the future.
We evaluated a rifaximin disc diffusion test and found it
substantially equivalent to an in-house rifaximin broth
microdilution test. The level of performance considered
acceptable for US Food and Drug Administration (FDA)
clearance in premarket notification of commercial anti-
microbial susceptibility systems is (among others) .89.9%
categorical agreement (same susceptible, intermediate or
resistant classification), ¡1.5% very major errors (false
susceptibility based on the number of resistant organisms)
and ¡3% major errors (false resistance based on the
number of susceptible isolates) (Richter & Ferraro, 2007).
Accepting an MIC ¢32 mgm l
21 as criterion for reduced
rifaximin susceptibility, a rifaximin inhibition zone of
,38 mm would represent a valid resistance breakpoint in
the 40 mg disc diffusion test described here.
We also found good correlation between the rifaximin and
rifampicin susceptibility testing results. The number of
discordant results (n58) concerning supposed resistance
based on the rifampicin Etest and rifaximin disc diffusion
test on C. difficile isolates could be seen as an argument
to introduce the criterion ‘intermediate’ for rifampicin
susceptibility testing. If we take the EUCAST breakpoints
for staphylococci (S¡0.06/R.0.5 mgm l
21) for the rifam-
picin Etest, the correlation would increase to 99.45% (five
discordant results) (EUCAST, 2010). Our suggestions for
preliminary breakpoints between susceptible, indeterm-
inate and resistant are summarized in Table 4 for the Etest
and the broth microdilution method to be validated in
future studies. In our opinion no reliable intermediate
breakpoint result can be given for the disc test; however, all
isolates in question showed rpoB mutations yielding an
amino acid change.
Rifamycin resistance is commonly the result of a mutation
that alters the b-subunit of RNA polymerase, reducing its
binding affinity for rifamycins (Struelens, 2003). This study
found rpoB mutations in all of the 62 strains showing
reduced susceptibility with the rifaximin broth microdilu-
tion test. Interestingly, only H502N and D492V mutations
showed discordant results between the rifampicin Etest and
the rifaximin broth microdilution test in the 184 strains
analysed, indicating a potential connection between muta-
tion in the rpoB region and the efficacy of the antibiotic
used. Future studies would enable examination of this
potential connection.
Our molecular investigations confirmed mutations result-
ing in amino acid substitutions in RpoB for all eight
isolates with discordant results with reduced susceptibility
to rifaximin and rifampicin. Interestingly, two strains
showing seven or eight silent mutations also showed
reduced susceptibility with the disc diffusion test, but not
with any of the other methods tested. Since no other
mutation could be found in the rpoB gene a mutation in
another gene influencing the activity of rifaximin has to be
Fig. 2. Rifaximin disc (40 mg) diffusion testing performed on 898
clinical C. difficile isolates yielding inhibition zone diameters
ranging from 6 mm (zero inhibition) to 78 mm.
Table 4. Suggested preliminary breakpoints
Rifaximin DD*
inhibition zone
(mm)
Rifaximin MIC
(mgm l
”1)
Rifampicin
MIC (mgm l
”1)
Susceptible ¢38 ¡0.25 ¡0.06
Intermediate – 0.5–16 0.012–16
Resistant ,38 ¢32 ¢32
*DD, disc diffusion.
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rifaximin against C. difficile, Ripa et al. (1987) previously
postulated the occurrence of chromosomal resistance
against rifaximin caused by mutation. In agreement with
these authors, we found a good correlation between rifaxi-
min and rifampicin susceptibility testing in vitro, under-
pinning the data obtained by O’Connor et al. (2008).
However, these results seem to be in contrast to the
findings of Jiang et al. (2010), who could not predict
rifaximin resistance by doing only rifampicin resistance
testing. Comparison of our data and those of O’Connor
et al. (2008) with the study by Jiang et al. (2010) suggests
that the use of acetone as solvent for rifaximin and
rifampicin by Jiang’s group is the reason for the differences.
To answer this question future studies should be
undertaken. However, in our opinion, in vitro susceptibil-
ity testing of rifampicin can be used to predict resistance to
rifaximin when done according to our method.
Rifaximin exhibits high activity against C. difficile in vitro,
with a very low MIC50 and a very high MIC90 (0.032 mgm l
21
and 1024 mgm l
21, respectively). By using our suggested
breakpoints (Table 4) as criteria for in vitro resistance, the
prevalence of resistance was 7.5% for all clinical isolates
tested. Among the so-called hypervirulent ribotype RT 027,
the prevalence of resistance was as high as 26%. These data
suggest that the development of resistance is in some way
dependent on the PCR ribotype investigated; this is in
concordance with general findings that some strains can
become resistant more easily than others, e.g. C. difficile PCR
ribotype 027, Mycobacterium tuberculosis spoligotype Beijing.
Susceptibility testing in the microbiology laboratory there-
fore could have an impact on the care and outcome of
patients with infection (Doern et al., 1994). The rifaximin
agar dilution and broth microdilution test systems facilitate
reading of MICs and are often considered as gold standards
for susceptibility testing. However, susceptibility testing by
the disc diffusion method has the advantages of simplicity,
low cost and a high degree of flexibility in the selection of
agents tested (Richter & Ferraro, 2007). Our results show
that rifaximin – despite its water-insolubility – may be a
suitable candidate for disc diffusion testing. Whether 40 mg
per disc is the ideal concentration must be examined in
further studies. Whether it was prudent to officially license a
substance ‘for treatment of all enteric infections caused by
susceptible organisms’ also remains to be answered.
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